151 related articles for article (PubMed ID: 38867863)
1. Factor XI inhibition in patients with acute coronary syndrome.
Raffo C; Capodanno D
Eur Heart J Suppl; 2024 Apr; 26(Suppl 1):i29-i34. PubMed ID: 38867863
[TBL] [Abstract][Full Text] [Related]
2. A Multicenter, Phase 2, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group, Dose-Finding Trial of the Oral Factor XIa Inhibitor Asundexian to Prevent Adverse Cardiovascular Outcomes After Acute Myocardial Infarction.
Rao SV; Kirsch B; Bhatt DL; Budaj A; Coppolecchia R; Eikelboom J; James SK; Jones WS; Merkely B; Keller L; Hermanides RS; Campo G; Ferreiro JL; Shibasaki T; Mundl H; Alexander JH;
Circulation; 2022 Oct; 146(16):1196-1206. PubMed ID: 36030390
[TBL] [Abstract][Full Text] [Related]
3. Safety and efficacy of factor XIa inhibition with milvexian for secondary stroke prevention (AXIOMATIC-SSP): a phase 2, international, randomised, double-blind, placebo-controlled, dose-finding trial.
Sharma M; Molina CA; Toyoda K; Bereczki D; Bangdiwala SI; Kasner SE; Lutsep HL; Tsivgoulis G; Ntaios G; Czlonkowska A; Shuaib A; Amarenco P; Endres M; Yoon BW; Tanne D; Toni D; Yperzeele L; von Weitzel-Mudersbach P; Sampaio Silva G; Avezum A; Dawson J; Strbian D; Tatlisumak T; Eckstein J; Ameriso SF; Weber JR; Sandset EC; Goar Pogosova N; Lavados PM; Arauz A; Gailani D; Diener HC; Bernstein RA; Cordonnier C; Kahl A; Abelian G; Donovan M; Pachai C; Li D; Hankey GJ
Lancet Neurol; 2024 Jan; 23(1):46-59. PubMed ID: 38101902
[TBL] [Abstract][Full Text] [Related]
4. Factor XIa inhibition with asundexian after acute non-cardioembolic ischaemic stroke (PACIFIC-Stroke): an international, randomised, double-blind, placebo-controlled, phase 2b trial.
Shoamanesh A; Mundl H; Smith EE; Masjuan J; Milanov I; Hirano T; Agafina A; Campbell B; Caso V; Mas JL; Dong Q; Turcani P; Christensen H; Ferro JM; Veltkamp R; Mikulik R; De Marchis GM; Robinson T; Lemmens R; Stepien A; Greisenegger S; Roine R; Csiba L; Khatri P; Coutinho J; Lindgren AG; Demchuk AM; Colorado P; Kirsch B; Neumann C; Heenan L; Xu L; Connolly SJ; Hart RG;
Lancet; 2022 Sep; 400(10357):997-1007. PubMed ID: 36063821
[TBL] [Abstract][Full Text] [Related]
5. Factor XI Inhibitors in Early Clinical Trials: A Meta-analysis.
Galli M; Laborante R; Ortega-Paz L; Franchi F; Rollini F; D'Amario D; Capodanno D; Tremoli E; Gibson CM; Mehran R; Angiolillo DJ
Thromb Haemost; 2023 Jun; 123(6):576-584. PubMed ID: 36841245
[TBL] [Abstract][Full Text] [Related]
6. Development of new anticoagulant in 2023: Prime time for anti-factor XI and XIa inhibitors.
Bentounes NK; Melicine S; Martin AC; Smadja DM; Gendron N
J Med Vasc; 2023 Apr; 48(2):69-80. PubMed ID: 37422330
[TBL] [Abstract][Full Text] [Related]
7. Asundexian: an oral small molecule factor XIa inhibitor for the treatment of thrombotic disorders.
D'Allesandro N; Cave B; Hough A
Future Cardiol; 2023 Aug; 19(10):477-486. PubMed ID: 37830334
[TBL] [Abstract][Full Text] [Related]
8. Pharmacology and Clinical Development of Factor XI Inhibitors.
Greco A; Laudani C; Spagnolo M; Agnello F; Faro DC; Finocchiaro S; Legnazzi M; Mauro MS; Mazzone PM; Occhipinti G; Rochira C; Scalia L; Capodanno D
Circulation; 2023 Mar; 147(11):897-913. PubMed ID: 36913497
[TBL] [Abstract][Full Text] [Related]
9. Determination of the Potential Clinical Benefits of Small Molecule Factor XIa Inhibitors in Arterial Thrombosis.
Wichaiyo S; Parichatikanond W; Visansirikul S; Saengklub N; Rattanavipanon W
ACS Pharmacol Transl Sci; 2023 Jul; 6(7):970-981. PubMed ID: 37470020
[TBL] [Abstract][Full Text] [Related]
10. Bleeding risk in patients prescribed dual antiplatelet therapy and triple therapy after coronary interventions: the ADAPTT retrospective population-based cohort studies.
Harris J; Pouwels KB; Johnson T; Sterne J; Pithara C; Mahadevan K; Reeves B; Benedetto U; Loke Y; Lasserson D; Doble B; Hopewell-Kelly N; Redwood S; Wordsworth S; Mumford A; Rogers C; Pufulete M
Health Technol Assess; 2023 May; 27(8):1-257. PubMed ID: 37435838
[TBL] [Abstract][Full Text] [Related]
11. Rationale and design of the AXIOMATIC-SSP phase II trial: Antithrombotic treatment with factor XIa inhibition to Optimize Management of Acute Thromboembolic events for Secondary Stroke Prevention.
Sharma M; Molina CA; Toyoda K; Bereczki D; Kasner SE; Lutsep HL; Tsivgoulis G; Ntaios G; Czlonkowska A; Shuaib A; Amarenco P; Endres M; Diener HC; Gailani D; Kahl A; Donovan M; Perera V; Li D; Hankey GJ
J Stroke Cerebrovasc Dis; 2022 Oct; 31(10):106742. PubMed ID: 36037679
[TBL] [Abstract][Full Text] [Related]
12. Safety of the oral factor XIa inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): a multicentre, randomised, double-blind, double-dummy, dose-finding phase 2 study.
Piccini JP; Caso V; Connolly SJ; Fox KAA; Oldgren J; Jones WS; Gorog DA; Durdil V; Viethen T; Neumann C; Mundl H; Patel MR;
Lancet; 2022 Apr; 399(10333):1383-1390. PubMed ID: 35385695
[TBL] [Abstract][Full Text] [Related]
13. Factor XI inhibitors for the prevention of cardiovascular disease: A new therapeutic approach on the horizon?
Santagata D; Donadini MP; Ageno W
Blood Rev; 2023 Nov; 62():101119. PubMed ID: 37580207
[TBL] [Abstract][Full Text] [Related]
14. News at XI: moving beyond factor Xa inhibitors.
Fredenburgh JC; Weitz JI
J Thromb Haemost; 2023 Jul; 21(7):1692-1702. PubMed ID: 37116752
[TBL] [Abstract][Full Text] [Related]
15. Trade-off of myocardial infarction vs. bleeding types on mortality after acute coronary syndrome: lessons from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) randomized trial.
Valgimigli M; Costa F; Lokhnygina Y; Clare RM; Wallentin L; Moliterno DJ; Armstrong PW; White HD; Held C; Aylward PE; Van de Werf F; Harrington RA; Mahaffey KW; Tricoci P
Eur Heart J; 2017 Mar; 38(11):804-810. PubMed ID: 28363222
[TBL] [Abstract][Full Text] [Related]
16. Pharmacological profile of asundexian, a novel, orally bioavailable inhibitor of factor XIa.
Heitmeier S; Visser M; Tersteegen A; Dietze-Torres J; Glunz J; Gerdes C; Laux V; Stampfuss J; Roehrig S
J Thromb Haemost; 2022 Jun; 20(6):1400-1411. PubMed ID: 35289054
[TBL] [Abstract][Full Text] [Related]
17. Triple versus guideline antiplatelet therapy to prevent recurrence after acute ischaemic stroke or transient ischaemic attack: the TARDIS RCT.
Bath PM; Woodhouse LJ; Appleton JP; Beridze M; Christensen H; Dineen RA; Flaherty K; Duley L; England TJ; Havard D; Heptinstall S; James M; Kasonde C; Krishnan K; Markus HS; Montgomery AA; Pocock S; Randall M; Ranta A; Robinson TG; Scutt P; Venables GS; Sprigg N
Health Technol Assess; 2018 Aug; 22(48):1-76. PubMed ID: 30179153
[TBL] [Abstract][Full Text] [Related]
18. Randomised controlled trial comparing efficacy and safety of high versus low Low-Molecular Weight Heparin dosages in hospitalized patients with severe COVID-19 pneumonia and coagulopathy not requiring invasive mechanical ventilation (COVID-19 HD): a structured summary of a study protocol.
Marietta M; Vandelli P; Mighali P; Vicini R; Coluccio V; D'Amico R;
Trials; 2020 Jun; 21(1):574. PubMed ID: 32586394
[TBL] [Abstract][Full Text] [Related]
19. Ticagrelor alone versus ticagrelor plus aspirin from month 1 to month 12 after percutaneous coronary intervention in patients with acute coronary syndromes (ULTIMATE-DAPT): a randomised, placebo-controlled, double-blind clinical trial.
Ge Z; Kan J; Gao X; Raza A; Zhang JJ; Mohydin BS; Gao F; Shao Y; Wang Y; Zeng H; Li F; Khan HS; Mengal N; Cong H; Wang M; Chen L; Wei Y; Chen F; Stone GW; Chen SL;
Lancet; 2024 May; 403(10439):1866-1878. PubMed ID: 38599220
[TBL] [Abstract][Full Text] [Related]
20. Milvexian: A Focus on a New Oral Anticoagulant that Targets Factor XIa for Thromboembolism Prophylaxis.
Birchansky J; Frishman WH
Cardiol Rev; 2024 Feb; ():. PubMed ID: 38305253
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]